SCHEMBL7314504

SCHEMBL7314504

NCCc1cn(CC(=O)O)c2ccc(OCc3ccc(C(=O)O)cc3)cc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTB4R Q15722 4/20 0.53
LTB4R2 Q9NPC1 4/20 0.53
EGFR P00533 5/20 0.50
IGF1R P08069 5/20 0.50
FLT4 P35916 5/20 0.50
KDR P35968 5/20 0.50
AKR1A1 P14550 1/20 0.50
AKR1B1 P15121 1/20 0.50
ITGB3 P05106 1/20 0.47
ITGA2B P08514 1/20 0.47
PPARD Q03181 3/20 0.46
PPARG P37231 2/20 0.46
PPARA Q07869 2/20 0.46
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
HTR1A P08908 1/20 0.44
HTR1D P28221 1/20 0.44
HTR1B P28222 1/20 0.44
RXRA P19793 1/20 0.44
RXRB P28702 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7310577 0.93 LTB4R (0.52) LTB4RLTB4R2EGFRIGF1RFLT4
SCHEMBL7310670 0.89 LTB4R (0.53) LTB4RLTB4R2EGFRIGF1RFLT4
SCHEMBL7318490 0.88 EGFR (0.56) LTB4RLTB4R2EGFRIGF1RFLT4
SCHEMBL7314343 0.87 LTB4R (0.51) LTB4RLTB4R2EGFRIGF1RFLT4
SCHEMBL7312021 0.86 EGFR (0.69) LTB4RLTB4R2EGFRIGF1RFLT4
SCHEMBL7310034 0.86 EGFR (0.54) LTB4RLTB4R2EGFRIGF1RFLT4
SCHEMBL7318188 0.84 EGFR (0.57) LTB4RLTB4R2EGFRIGF1RFLT4
SCHEMBL7312297 0.84 LTB4R (0.52) LTB4RLTB4R2EGFRIGF1RFLT4
SCHEMBL7316830 0.82 EGFR (0.52) LTB4RLTB4R2EGFRIGF1RFLT4
SCHEMBL7315456 0.82 EGFR (0.54) LTB4RLTB4R2EGFRIGF1RFLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010007877-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION 2001-07-12 US claimed
WO-2001034146-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2001-05-17 WO claimed
US-20010007877-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION 2001-07-12 US disclosed
WO-2001034146-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2001-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010007877-A1 NOVEL ANTI-INFECTIVES CTSL, MMP8, SERPINB1 LTB4R 1512/4885LTB4R2 1564/4885EGFR 4683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.